Fig. 6: I5 reduces in vivo PANC1 tumor growth.
a Summary of the in vivo experimental design for the pre-treated PANC1 cell xenograft in vivo studies. Schematic created with BioRender.com. b Growth curves indicating tumor take (left, defined as no. tumors formed/no. of injections at the indicated time point) or the mean tumor volume (mm3) (right) ± SD over 28 days following injection of 1 × 105 Control diluent-treated or I5-treated PANC1 cells. (no. of injections = 8–9). c Quantification of the mean tumor volume and mean weights (g) ± SD for control (c) and I5-pre-treated tumors (no. of injections = 8–9). Statistical significance was evaluated with Student’s 2-tailed t-test (**p < 0.01, ***p < 0.001). d Indirect calorimetry analyses of mice treated with I5. Left: Respiratory exchange ratio (RER) was determined as VCO2/VO2 and right: Energy expenditure (EE) was calculated as (3.185 + 1.232 x RER) x VO2. Shown are the mean RER and mean EE (Kcal/h/Kg) values ± SD for mice implanted treated intravenously with I5 (1.4 mg/Kg) or physiological saline (i.e., Sham) as a function of time (24 h). e Summary of the in vivo experimental design for the treatment of mice harboring PANC1 xenografted tumors. Schematic created with BioRender.com. f Average fold change in tumor volume ± SEM in mice bearing PANC1 xenografts and treated with diluent control (Control), I5 (1.4 mg/kg i.p. or r.o.; 3-times per week) and compared to d0 (n = 5-7 tumors/group). g Mean fold change in tumor volume ± SEM (left) or tumor weight ± SEM (right) determined at treatment cessation. *p < 0.05, as determined by one-way ANOVA with Dunnett post-test, compared to Control. ns not significant; g gram; d0 day 0.
